Nook Therapeutics to hyperactivate ‘the brains of the immune machine’ with $54M release

Cor­ner Ther­a­peu­tics’ $54 mil­lion Se­ries A will probably be used to deliver new im­munother­a­pies for can­cer and in­fec­tious dis­eases in­to the clin­ic, the com­pa­big apple mentioned Thurs­day.

The beginning­up is led by way of Steve Altschuler, who co-found­ed Spark Ther­a­peu­tics and used to be pre­vi­ous­ly CEO of the Chil­dren’s Hos­pi­tal of Philadel­phia. Altschuler serves as the person­ag­ing di­rec­tor of well being­care ven­tures at Ziff Cap­i­tal Section­ners, which led Cor­ner’s Se­ries A lift. Cock­rell In­ter­ests, Ta­nis Ven­tures and San­dia Grasp­ings al­so con­tributed to the lift.

Release this newsletter right away by way of turning into a unfastened subscriber.
You’ll get get admission to to unfastened articles each and every month, plus you’ll be able to customise what newsletters get delivered on your inbox each and every week, together with breaking information.

Author: OpenAI